A U.S. judge on Monday rejected Bristol Myers Squibb’s bid to dismiss a $6.7 billion lawsuit claiming it cheated shareholders of the former Celgene by delaying federal approval for three drugs, including the cancer treatment Breyanzi, by specified deadlines.
While dismissing some claims, U.S. District Judge Jesse Furman in Manhattan said the plaintiff UMB Bank may pursue some claims on behalf of the shareholders, including for breach of contract.
(Reporting by Stempel in New York; Editing by Chris Reese)
Copyright 2026 Reuters. Click for restrictions.
Was this article valuable?
Here are more articles you may enjoy.
State Farm Must Give Up Trade Secrets in Claims Lawsuits, but Under Court Review 
Moody’s Says Heat, Water Scarcity Driving Stranded-Asset Risks 
NJ School Board Not Liable for Boy’s Shooting at Football Game With No Metal Detector 
Trump Wins Permission to Revise BBC Suit to Remove Brand Damage 
Want to stay up to date?
Get the latest insurance news
sent straight to your inbox.